Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Lactobacillus salivarius UCC118 and Reduced Gastrointestinal Infections

Research synthesisVery low evidenceMixed effect size3 studies · 3 beneficial · 0 neutral · 0 harmful

Across 3 review-level studies, all reported beneficial effects of Lactobacillus salivarius UCC118 on reducing gastrointestinal infections, with effect sizes ranging from small to moderate. No human trial data were available; the evidence is derived from animal models and genomic characterizations. Doses, forms, and study durations were not reported.

Caveats: All studies are reviews or genomic reports, not original controlled human trials. Evidence comes from mouse models of Listeria infection and in vitro bacteriocin characterization, so direct translation to human gastrointestinal infections is uncertain. No human-specific dosing, form, or population data were extracted.

Generated May 11, 2026
3 of 3 papers
Back to top